Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 6/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559071 | 0.87 | BRAF (0.35) | BRAF | |
| SCHEMBL4478022 | 0.87 | RXRA (0.37) | RXRARXRBBRAFNOTUM | |
| SCHEMBL4465334 | 0.85 | NR1I2 (0.35) | BRAFNOTUM | |
| SCHEMBL4501468 | 0.85 | BRAF (0.34) | BRAFNOTUM | |
| SCHEMBL4508141 | 0.85 | ESRRA (0.38) | RXRARXRBBRAFNOTUM | |
| SCHEMBL4484187 | 0.84 | NR1I2 (0.38) | BRAFNOTUM | |
| SCHEMBL4462231 | 0.84 | BRAF (0.37) | BRAF | |
| SCHEMBL4462964 | 0.84 | BRAF (0.33) | BRAFNOTUM | |
| SCHEMBL4462646 | 0.83 | BRAF (0.33) | BRAF | |
| SCHEMBL4471365 | 0.83 | BRAF (0.33) | BRAFNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569568-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070032492-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-7166628-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1567507-B1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1567507-A1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102492-A1 | Cytokine inhibitors | IL1A, IL1B, IL1RN | LMNA 4141/4885RXRA 1466/4885RXRB 1522/4885 |
| US-20070032492-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1RN | LMNA 4573/4885RXRA 1334/4885RXRB 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.